CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Globenewswire
Financial Performance: CytoMed Therapeutics reported a reduced net loss of US$1.85 million for the year ending December 31, 2024, an improvement from US$3.03 million in 2023, with cash balances of US$3.64 million and plans for strategic growth in cellular immunotherapy targeting cancers and autoimmune diseases.
Clinical Developments: The company is advancing its clinical trials, including the ANGELICA trial for CAR T therapy using gamma delta T cells, and plans to expand operations in Malaysia and India while exploring partnerships in China to enhance its manufacturing capabilities and reach more patients.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
